M
IMEPro
K71.0 Internal Medicine
Updated March 2026

Toxic liver disease with cholestasis

ICD-10 Code: K71.0 · Body Part: Lumbar Spine

QME Evaluation Process

Liver function tests, imaging, biopsy if indicated, toxic exposure history documentation. Chapter 6 digestive impairment. Causation analysis for occupational chemical exposure.

Typical Impairment Rating

10-40% WPI based on liver function and progression

AMA Guides Edition

5th Edition

Common Treatments

+ Remove toxic exposure
+ Hepatoprotective medication
+ Monitoring
+ Liver transplant for end-stage

Related Conditions

Body Part Guide

Lumbar Spine Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Toxic liver disease with cholestasis

Find a QME Specialist

Browse QME-certified physicians who evaluate toxic liver disease with cholestasis and related lumbar spine conditions in California.

Browse Neurology Physicians →

Frequently Asked Questions

What is Toxic liver disease with cholestasis (K71.0)?

Toxic liver disease with cholestasis is an ICD-10 diagnosis code (K71.0) classified under Internal Medicine conditions. It affects the Lumbar Spine and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is K71.0 rated for impairment?

The typical whole person impairment (WPI) range for Toxic liver disease with cholestasis is 10-40% WPI based on liver function and progression. The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for K71.0?

Liver function tests, imaging, biopsy if indicated, toxic exposure history documentation. Chapter 6 digestive impairment. Causation analysis for occupational chemical exposure.

What treatments are common for Toxic liver disease with cholestasis?

Common treatments for Toxic liver disease with cholestasis include Remove toxic exposure, Hepatoprotective medication, Monitoring, Liver transplant for end-stage. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.